01Role and principlesWho benefits and the main preventive aims.
Lymphatic failure impairs local immune clearance and produces oedema, skin tension and tissue change. Fissures, toe-web fungus, dermatitis, ulcers, lymph leakage and minor trauma then create bacterial entry points. Cellulitis can damage superficial lymphatics further, increasing swelling and setting up a recurrence cycle. Prevention therefore begins with verifying that previous episodes were truly bacterial, treating portals of entry, controlling oedema and supporting movement and weight management. Acute venous hypertension, lipodermatosclerosis, contact dermatitis and DVT can mimic cellulitis; several short courses for recrudescence after incomplete treatment may represent one episode rather than repeated new infections. Accurate dates, clinical features, response and treatment duration matter before exposing someone to long-term antibiotics.
Two national specialist frameworks overlap but are not identical. The 2025 BLS/LSN guideline is specifically for cellulitis in lymphoedema and places prophylaxis decisions with a lymphoedema specialist or microbiologist. It considers prophylaxis after two or more attacks in a year, adjusts phenoxymethylpenicillin for BMI at least 33, and uses doxycycline then clarithromycin for penicillin-allergic patients, with erythromycin in pregnancy. NICE NG141 concerns cellulitis and erysipelas generally: prophylaxis is not routine, but a specialist may consider a trial after at least two separate episodes treated in hospital or under specialist advice during the previous 12 months; NICE uses erythromycin for penicillin allergy and requires review at least every six months. The prescriber should state which guideline and indication govern the regimen, reconcile pregnancy, allergy, interactions and organ function, and review rather than continuing automatically.
Key points
- An acute attack needs prompt assessment and a full acute-treatment course; do not continue prophylactic-dose antibiotic as though it treats active cellulitis, and stop prophylaxis while acute antibiotics are taken.
- Control swelling with specialist lymphoedema therapy and compression when tolerated, because compression and decongestive care reduce recurrence; remove a garment during an attack if it is painful and reintroduce it as inflammation settles.
- Treat portals and mimics: daily emollient skin care, wounds, dermatitis, lymphorrhoea, interdigital maceration and fungal infection; repeated venous inflammation or incompletely treated cellulitis should not be miscounted as new attacks.
- The 2025 BLS/LSN lymphoedema-specific guideline says prophylaxis decisions and duration should be made with the local specialist lymphoedema service, or microbiology if none exists.
- BLS/LSN says consider prophylaxis after two or more attacks per year, after verifying bacterial episodes and addressing reversible factors; phenoxymethylpenicillin is 250 mg orally every 12 hours, or 500 mg every 12 hours if BMI is at least 33.
- Under BLS/LSN, penicillin allergy uses doxycycline 100 mg orally daily; if doxycycline is not tolerated, clarithromycin 250 mg daily is recommended, while erythromycin 250 mg every 12 hours is used in pregnancy.
- NICE NG141 addresses recurrent cellulitis generally: do not routinely offer prophylaxis; specialists may consider a trial after at least two separate hospital- or specialist-treated episodes in the previous 12 months and review at least every six months.
- NICE's generic adult prophylaxis table uses phenoxymethylpenicillin 250 mg orally twice daily or erythromycin 250 mg twice daily for penicillin allergy; it does not supply the BLS BMI adjustment or its doxycycline pathway.
- After one successful year, BLS/LSN advises considering discontinuation if risk factors are controlled; continue another year if significant risks persist, and consider lifelong treatment after relapse with persistent risks, with at least annual review.
02Assessment and patient selectionRisk features, eligibility and important cautions.
Pain, warmth, expanding erythema and increased swelling, sometimes with fever or systemic upset, support cellulitis. Mark the visible edge and record temperature, observations and baseline limb size.
Inspect interdigital spaces, nails, folds, wounds, ulcers, dermatitis, scratches and lymphorrhoea. A small fissure or fungal infection may be clinically more important than a large intact swollen area.
Bilateral erythema, itch, scaling, chronic induration or improvement with elevation can suggest dermatitis, venous hypertension or lipodermatosclerosis. Repeated antibiotics without re-examination promote harm.
Record distinct onset and resolution dates, severity, admission or specialist treatment, prescribed duration and interval to recurrence. Relapse within weeks may indicate an incompletely treated original attack.
03Baseline assessmentMeasurements that guide the plan and track progress.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Clinical episode recordFirst step - Why
- Verify the number, timing, severity and treatment of separate bacterial cellulitis attacks before prophylaxis is considered.
- Interpretation and limitations
- Two documented attacks per year support BLS consideration; NICE's threshold additionally specifies at least two separate hospital- or specialist-treated episodes in 12 months.
- 02
Skin, toe-web and wound assessment - Why
- Identify fungal infection, fissures, dermatitis, ulcers, lymph leakage and other reversible bacterial entry points.
- Interpretation and limitations
- A treatable portal strengthens the non-antibiotic plan and may remove the need for prophylaxis if episodes stop after correction.
- 03
Oedema and compression review - Why
- Measure swelling, inspect garment fit and assess adherence, mobility and whether venous or obesity-related load remains uncontrolled.
- Interpretation and limitations
- Persistent poorly controlled oedema sustains risk; effective compression after acute inflammation has settled is part of recurrence prevention rather than an optional accessory.
- 04
Allergy and prescribing assessment - Why
- Verify the reaction to penicillin and review pregnancy, hepatic or renal impairment, interactions, microbiology and previous antibiotic exposure.
- Interpretation and limitations
- Intolerance is not synonymous with immediate hypersensitivity. The safe alternative differs between the BLS lymphoedema pathway and NICE's generic table, so the governing plan must be explicit.
04InterventionsLifestyle, treatment and escalation options.
01Prevention pathwayAfter recovery from cellulitisFirst stepUse once acute infection has been adequately treated and the patient can resume lymphoedema self-management.+
- 1Confirm that erythema, systemic illness and tenderness are resolving, reintroduce well-fitting compression when comfortable, and restore movement and oedema-control routines.
- 2Inspect and treat toe-web fungus, fissures, dermatitis, wounds, ulcers and lymphorrhoea; teach daily washing, careful drying, bland emollient use and prompt protection of skin injury.
- 3Record the attack as a dated episode with severity, regimen and duration, and give a clear action plan for familiar recurrence or red-flag deterioration.
- 4Address weight, mobility, garment fit and access barriers with the specialist lymphoedema service rather than relying on antibiotics alone.
02BLS specialist pathwayPreferred BLS specialist prophylaxisPreferredUse for two or more credible attacks in a year when BLS lymphoedema-specific guidance governs, after risk factors and mimics have been reviewed.+
- 1Make the decision with the local specialist lymphoedema service, or microbiology if no such service exists, after verifying separate bacterial episodes and correcting reversible causes.
- 2AlternativeUse phenoxymethylpenicillin 250 mg orally every 12 hours, increasing to 500 mg every 12 hours when BMI is at least 33; select the BLS allergy alternative only after checking the allergy history.
- 3After one successful year consider stopping if risks are controlled; continue for a further year if major risks persist, and consider lifelong prophylaxis after relapse with persistent risks.
- 4Review long-term therapy at least annually, reconsider stopping whenever risks improve, and reassess diagnosis and specialist options if attacks continue.
03NICE generic pathwaySpecialist trial of prophylaxisUse when applying NICE NG141 to an adult with at least two separate hospital- or specialist-treated episodes in the previous 12 months.+
- 1Do not offer prophylaxis routinely; use shared decision-making about severity, complications, underlying oedema or venous disease, resistance and the person's preference.
- 2Choose phenoxymethylpenicillin 250 mg orally twice daily, or erythromycin 250 mg orally twice daily for penicillin allergy, informed by microbiology and recent antibiotic exposure.
- 3Advise about adverse effects and urgent assessment for recurrence, arrange review within six months, and review at least every six months thereafter.
- 4At review assess success and discuss continuing, stopping or changing; treat any acute recurrence with a full treatment regimen and stop or change prophylaxis as NICE directs.
05Medicines and treatment safetyRegimens, contraindications and review points.
Phenoxymethylpenicillin for BLS lymphoedema prophylaxis
Take 250 mg orally every 12 hours; use 500 mg every 12 hours if BMI is at least 33. Review after one successful year for stopping or extension.Confirm the nature of any penicillin allergy. Balance resistance and long-term adverse effects; stop during acute-treatment antibiotics. Continue another year only for persistent risks and review lifelong use at least annually.
Doxycycline for BLS penicillin-allergy prophylaxis
Take 100 mg orally once daily while specialist prophylaxis remains indicated; reassess at one year and at least annually if continued long term.The BLS/LSN regimen is not used in pregnancy; its pregnancy alternative is erythromycin 250 mg every 12 hours. Confirm the allergy history and review continued need rather than prescribing indefinitely.
Phenoxymethylpenicillin for NICE generic prophylaxis
Take 250 mg orally twice daily as a specialist trial, with review within six months and at least every six months while continued.Not for routine use or active cellulitis. Check allergy, microbiology, prior antibiotics and organ-specific prescribing information; discuss resistance and stop or change if cellulitis recurs.
Erythromycin for NICE penicillin-allergy prophylaxis
Take 250 mg orally twice daily as the NICE specialist prophylaxis alternative, reviewing within six months and at least every six months thereafter.Use only after penicillin-allergy assessment and specialist selection. Review within six months and at least every six months while continued; reassess adverse effects, antimicrobial resistance and any breakthrough infection.
06Targets, monitoring and follow-upResponse, safety and longer-term review.
- Review skin, toe webs, nails, wounds, lymphorrhoea, dermatitis, oedema volume and compression fit at every prevention review, treating new portals promptly.
- Under NICE, review prophylaxis within and at least every six months; under BLS long-term prophylaxis needs at least annual review and repeated consideration of discontinuation.
- Monitor allergy, rash, gastrointestinal effects, antibiotic-associated diarrhoea and breakthrough infection, and reassess whether prophylaxis still outweighs resistance and adverse-effect risks.
- If cellulitis breaks through, reassess urgently, use acute-treatment dosing, and involve lymphoedema specialists or microbiology before changing or extending prophylaxis.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Compression prevents recurrence
Once acute pain and inflammation permit, restoring effective compression addresses the oedema that sustains infection risk. Antibiotic prophylaxis cannot compensate for an unmanageable or poorly fitting garment.
Allergy pathways differ
The current BLS lymphoedema pathway uses doxycycline then clarithromycin, whereas NICE's general cellulitis table uses erythromycin. Name the governing recommendation and patient context in the prescription plan.
BMI modifier is specialist-specific
The BLS/LSN phenoxymethylpenicillin increase to 500 mg twice daily at BMI 33 or above does not appear in NICE's generic adult prophylaxis table.
Prophylaxis has a stop plan
Successful suppression is an opportunity to review skin and oedema control, then reduce unnecessary exposure. Persistent risks or relapse may justify longer treatment, but not unreviewed automatic renewal.
08Common pitfallsFrequent interpretation and management errors.
- 01
Mixing the BLS allergy regimen with the NICE threshold and review schedule without naming either framework makes dosing decisions impossible to audit.
- 02
Continuing a prophylactic dose as treatment during an acute attack provides inadequate therapy and delays severity assessment.
- 03
Ignoring toe-web fungus, fissures, wounds, lymph leakage and poorly controlled oedema leaves the main modifiable recurrence drivers untreated.
- 04
Renewing prophylaxis indefinitely without assessing success, adverse effects, resistance, risk-factor improvement and a stop point contradicts both guideline approaches.